A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID‐19 in skilled care facilities
Open Access
- 22 February 2021
- journal article
- research article
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 69 (4), 868-873
- https://doi.org/10.1111/jgs.17090
Abstract
Background Residents of nursing homes and long‐term care facilities are at increased risk for severe coronavirus disease‐19 (COVID‐19) but may not be able to access monoclonal antibody therapies offered at outpatient infusion centers due to frailty and logistical issues. We describe a mobile monoclonal antibody infusion program for patients with COVID‐19 in skilled nursing facilities and provide descriptive data on its outcomes. Design Retrospective cohort study. Setting Collaboration between Mayo Clinic and skilled nursing facilities in Southeast Minnesota was developed to administer anti‐spike monoclonal antibodies under the FDA Emergency Use Authorization. Participants Seventy five residents of skilled nursing facilities at high risk of COVID‐19 complications. Exposure Emergency use treatment with bamlanivimab and casirivimab–imdevimab. Measurements Hospitalization and medically attended visits. Results The mobile infusion unit, staffed by Mayo Clinic Infusion Therapy registered nurses and supported by the skilled nursing facility staff, infused anti‐spike monoclonal antibodies to 45 of 75 patients (average age, 77.8 years) in December 2020. The infusions occurred at an average of 4.3 days after COVID‐19 diagnosis. Fourteen days after infusion, there were no deaths, two emergency department visits, and three hospitalizations, for a combined event rate of 11.1%. There was one reported adverse event. Conclusion The implementation of a mobile infusion unit embedded in a collaborative process resulted in rapid infusion of monoclonal antibodies to high‐risk COVID‐19 patients in skilled nursing facilities, who would otherwise be unable to access the novel therapies. The therapies were well tolerated and appear beneficial. Further study is warranted to explore the scalability and efficacy of this program.Keywords
This publication has 6 references indexed in Scilit:
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19New England Journal of Medicine, 2021
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19New England Journal of Medicine, 2021
- COVID-19 and the elderly: insights into pathogenesis and clinical decision-makingAging Clinical and Experimental Research, 2020
- Why does COVID-19 disproportionately affect older people?Aging, 2020
- Epidemiology of Covid-19 in a Long-Term Care Facility in King County, WashingtonNew England Journal of Medicine, 2020
- COVID‐19 diagnosis and management: a comprehensive reviewJournal of Internal Medicine, 2020